Diet, Genetics, and the Gut Microbiome Drive Dynamic Changes in Plasma Metabolites

Cell Reports

Volumn 22, Issue 11, 2018, Pages 3072-3086

  Fujisaka, Shiho ^a,b   Avila Pacheco, Julian ^c   Soto, Marion ^a   Kostic, Aleksandar ^a   Dreyfuss, Jonathan M ^a,d   Pan, Hui ^a,d   Ussar, Siegfried ^a,e   Altindis, Emrah ^a   Li, Ning ^f   Bry, Lynn ^f   Clish, Clary B ^c   Kahn, C Ronald ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Boston University   (United States)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

antibiotics; bile acids; cecal metabolomics; diabetes; diet; gut microbiome; obesity; serum lipids; serum metabolomics; TMAO

Indexed keywords

DNA; INSULIN; METRONIDAZOLE; RNA; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; CORRELATIONAL STUDY; DIET; DNA SEQUENCE; GENETICS; INSULIN RESISTANCE; INTESTINE FLORA; LIPID DIET; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; METABOLISM; METABOLITE; METABOLOMICS; METAGENOME; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PLASMA; PREDICTION; PRIORITY JOURNAL; RNA SEQUENCE; ANIMAL; HUMAN; OBESITY; PATHOLOGY; PROCEDURES;

ANIMALS; DIET, HIGH-FAT; GASTROINTESTINAL MICROBIOME; HUMANS; METABOLOMICS; MICE; OBESITY;

EID: 85043592218     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.02.060     Document Type: Article

References (51)

1. Allegretti, J.R., Kearney, S., Li, N., Bogart, E., Bullock, K., Gerber, G.K., Bry, L., Clish, C.B., Alm, E., Korzenik, J.R., Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol. Ther. 43 (2016), 1142–1153.
2. Almind, K., Kahn, C.R., Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes 53 (2004), 3274–3285.
3. Bouter, K.E., van Raalte, D.H., Groen, A.K., Nieuwdorp, M., Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. Gastroenterology 152 (2017), 1671–1678.
4. Brown, J.M., Hazen, S.L., Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery. J. Biol. Chem. 292 (2017), 8560–8568.
5. Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 (2015), 577–591.
6. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 111 (2014), 2247–2252.
7. Chen, T., Zheng, X., Ma, X., Bao, Y., Ni, Y., Hu, C., Rajani, C., Huang, F., Zhao, A., Jia, W., Jia, W., Tryptophan Predicts the Risk for Future Type 2 Diabetes. PLoS ONE, 11, 2016, e0162192.
8. Cho, I., Yamanishi, S., Cox, L., Methé B.A., Zavadil, J., Li, K., Gao, Z., Mahana, D., Raju, K., Teitler, I., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488 (2012), 621–626.
9. Dambrova, M., Latkovskis, G., Kuka, J., Strele, I., Konrade, I., Grinberga, S., Hartmane, D., Pugovics, O., Erglis, A., Liepinsh, E., Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels. Exp. Clin. Endocrinol. Diabetes 124 (2016), 251–256.
10. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., Bäckhed, F., Mithieux, G., Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156 (2014), 84–96.
11. Ertunc, M.E., Hotamisligil, G.S., Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J. Lipid Res. 57 (2016), 2099–2114.
12. Fujisaka, S., Ussar, S., Clish, C., Devkota, S., Dreyfuss, J.M., Sakaguchi, M., Soto, M., Konishi, M., Softic, S., Altindis, E., et al. Antibiotic effects on gut microbiota and metabolism are host dependent. J. Clin. Invest. 126 (2016), 4430–4443.
13. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
14. Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., Willemsen, E.C.L., Renooij, W., Murzilli, S., Klomp, L.W.J., Siersema, P.D., Schipper, M.E.I., Danese, S., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
15. Gall, W.E., Beebe, K., Lawton, K.A., Adam, K.-P., Mitchell, M.W., Nakhle, P.J., Ryals, J.A., Milburn, M.V., Nannipieri, M., Camastra, S., et al., RISC Study Group. α-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE, 5, 2010, e10883.
16. Holmes, E., Li, J.V., Marchesi, J.R., Nicholson, J.K., Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 16 (2012), 559–564.
17. Jakobsdottir, G., Xu, J., Molin, G., Ahrné S., Nyman, M., High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS ONE, 8, 2013, e80476.
18. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125 (2015), 386–402.
19. Kameyama, K., Itoh, K., Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ. 29 (2014), 427–430.
20. Kim, E., Coelho, D., Blachier, F., Review of the association between meat consumption and risk of colorectal cancer. Nutr. Res. 33 (2013), 983–994.
21. Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., Terasawa, K., Kashihara, D., Hirano, K., Tani, T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun., 4, 2013, 1829.
22. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Bäckhed, F., From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 165 (2016), 1332–1345.
23. Kuda, O., Brezinova, M., Rombaldova, M., Slavikova, B., Posta, M., Beier, P., Janovska, P., Veleba, J., Kopecky, J. Jr., Kudova, E., et al. Docosahexaenoic Acid-Derived Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) With Anti-inflammatory Properties. Diabetes 65 (2016), 2580–2590.
24. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al., MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546.
25. Lynch, S.V., Pedersen, O., The Human Intestinal Microbiome in Health and Disease. N. Engl. J. Med. 375 (2016), 2369–2379.
26. Menni, C., Fauman, E., Erte, I., Perry, J.R.B., Kastenmüller, G., Shin, S.-Y., Petersen, A.-K., Hyde, C., Psatha, M., Ward, K.J., et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62 (2013), 4270–4276.
27. Mikkelsen, K.H., Frost, M., Bahl, M.I., Licht, T.R., Jensen, U.S., Rosenberg, J., Pedersen, O., Hansen, T., Rehfeld, J.F., Holst, J.J., et al. Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS ONE, 10, 2015, e0142352.
28. Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., Haqq, A.M., Shah, S.H., Arlotto, M., Slentz, C.A., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9 (2009), 311–326.
29. Nieuwdorp, M., Gilijamse, P.W., Pai, N., Kaplan, L.M., Role of the microbiome in energy regulation and metabolism. Gastroenterology 146 (2014), 1525–1533.
30. Parks, B.W., Sallam, T., Mehrabian, M., Psychogios, N., Hui, S.T., Norheim, F., Castellani, L.W., Rau, C.D., Pan, C., Phun, J., et al. Genetic architecture of insulin resistance in the mouse. Cell Metab. 21 (2015), 334–346.
31. Pedersen, H.K., Gudmundsdottir, V., Nielsen, H.B., Hyotylainen, T., Nielsen, T., Jensen, B.A., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al., MetaHIT Consortium. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535 (2016), 376–381.
32. Perry, R.J., Peng, L., Barry, N.A., Cline, G.W., Zhang, D., Cardone, R.L., Petersen, K.F., Kibbey, R.G., Goodman, A.L., Shulman, G.I., Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534 (2016), 213–217.
33. Rhee, E.P., Cheng, S., Larson, M.G., Walford, G.A., Lewis, G.D., McCabe, E., Yang, E., Farrell, L., Fox, C.S., O'Donnell, C.J., et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121 (2011), 1402–1411.
34. Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., Griffin, N.W., Lombard, V., Henrissat, B., Bain, J.R., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013, 1241214.
35. Savage, D.C., Dubos, R., Alterations in the mouse cecum and its flora produced by antibacterial drugs. J. Exp. Med. 128 (1968), 97–110.
36. Schroeder, B.O., Bäckhed, F., Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 22 (2016), 1079–1089.
37. Smith, C.A., O'Maille, G., Want, E.J., Qin, C., Trauger, S.A., Brandon, T.R., Custodio, D.E., Abagyan, R., Siuzdak, G., METLIN: a metabolite mass spectral database. Ther. Drug Monit. 27 (2005), 747–751.
38. Tamburini, S., Shen, N., Wu, H.C., Clemente, J.C., The microbiome in early life: implications for health outcomes. Nat. Med. 22 (2016), 713–722.
39. Tang, W.H.W., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., Wu, Y., Hazen, S.L., Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368 (2013), 1575–1584.
40. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10 (2009), 167–177.
41. Tolhurst, G., Heffron, H., Lam, Y.S., Parker, H.E., Habib, A.M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., Gribble, F.M., Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61 (2012), 364–371.
42. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
43. Ussar, S., Griffin, N.W., Bezy, O., Fujisaka, S., Vienberg, S., Softic, S., Deng, L., Bry, L., Gordon, J.I., Kahn, C.R., Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. Cell Metab. 22 (2015), 516–530.
44. Ussar, S., Fujisaka, S., Kahn, C.R., Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol. Metab. 5 (2016), 795–803.
45. Wang, T.J., Larson, M.G., Vasan, R.S., Cheng, S., Rhee, E.P., McCabe, E., Lewis, G.D., Fox, C.S., Jacques, P.F., Fernandez, C., et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17 (2011), 448–453.
46. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
47. Wang, T.J., Ngo, D., Psychogios, N., Dejam, A., Larson, M.G., Vasan, R.S., Ghorbani, A., O'Sullivan, J., Cheng, S., Rhee, E.P., et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J. Clin. Invest. 123 (2013), 4309–4317.
48. Wikoff, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., Siuzdak, G., Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106 (2009), 3698–3703.
49. Yamada, H., Umemoto, T., Kakei, M., Momomura, S.I., Kawakami, M., Ishikawa, S.E., Hara, K., Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice. Nutr. Metab. (Lond.), 14, 2017, 33.
50. Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
51. Zhang, L.S., Davies, S.S., Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med., 8, 2016, 46.